Nicholas Huntington, Director of Research, Cancer Immunology at Monash University, shared on LinkedIn:
“~80% of patients on anti-PD1/L1 don’t benefit. Why?
We argue the problem starts upstream: a weak Innate Immune Setpoint leaves T cell priming suboptimal in most patients before checkpoint blockade even comes into play.
In this issue of Nature Cancer, we propose that the NK cell – DC inflammatory loop is a dominant pathway in setting an optimal Innate Immune Setpoint for efficient T cell priming.
The implication for next-gen immunotherapy: fix the setpoint first, then target its downstream product, TAA/neoantigen-specific T cells.
A rewarding deep dive into NK–DC loops in solid tumors, and the emerging therapies designed to target the Innate Immune Setpoint with Rebecca Delconte, Michael Chopin, Xiangpeng Meng.”
Title: Natural killer cell inflammatory circuits in antitumor immunity
Authors: Nicholas Huntington, Xiangpeng Meng, Michael Chopin, Rebecca Delconte
You may also be interested in:
Victor Moreno: Tumor Growth vs Antitumor Immunity, A New Strategy to Fight MSS Colorectal Cancer